Our overarching vision within the Centre is to apply our skills and expertise in developing innovative personalised diagnostic, prognostic and therapeutic strategies. Research focuses on the discovery of new biomarkers for earlier diagnosis, monitoring disease progression and response to treatment, and identifying those individuals at risk of disease, and developing targeted treatments.
The Centre for Cancer Biomarkers & Biotherapeutics is located in the Barts Cancer Institute, a CRUK Centre of Excellence dedicated to delivering world-leading research.
We comprise a multidisciplinary team of surgeons, clinicians, pathologists, basic scientists, biobanking professionals and bioinformaticians; working together towards a common goal.
Our overarching vision is to apply our skills and expertise in developing innovative personalised diagnostic, prognostic and therapeutic strategies.
Research focuses on the discovery of new biomarkers for earlier diagnosis, monitoring disease progression and response to treatment, and identifying those individuals at risk of disease, and developing targeted treatments.
Our activities are enhanced by our involvement with local and national biobanks: within the Centre, we have biobanking professionals for specimen management and bioinformaticians for analysing molecular data. Our diversity of research specialities offers an unparalleled opportunity to create a biobanking system in which clinical, molecular and pathologic data are linked.
We are committed to enhancing the teaching experience both for students and the general public through our teaching and outreach activities.
Centre Lead
Deputy Centre Lead
John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ
Professor of Bioinformatics
Professor of Molecular Pathology and Biomarkers
Professor of Molecular Oncology
Professor of Molecular Oncology
Lecturer in Digital Pathology
Lecturer in Digital Pathology
Professor of Radionuclide Imaging and Therapy
Professor of Medical Oncology
Professor of Cancer Cell and Gene Therapy
Researchers have uncovered a mechanism that makes some cancer cells especially vulnerable to experimental drugs known as ATR inhibitors. The findings could support the development of tests to identify the patients most likely to benefit.
Publications 17 August 2026
Scientists have carried out one of the largest and most comprehensive studies to date of the genetic and clinical factors associated with cancer in British Bangladeshi and Pakistani people. The findings could help inform future efforts to make cancer screening and risk assessment more equitable.
Publications 7 August 2026
Queen Mary University of London has launched a new company, Procyon Diagnostics, to provide pioneering early cancer detection tests. The company’s first test, PancRISK, offers new hope for detecting pancreatic cancer earlier, building on over 15 years of research by Professor Tatjana Crnogorac-Jurcevic at Queen Mary’s Barts Cancer Institute (BCI), funded by the Pancreatic Cancer Research Fund.
General News 29 October 2025